Aortic stenosis classification: Difference between revisions
(8 intermediate revisions by 2 users not shown) | |||
Line 10: | Line 10: | ||
==Overview== | ==Overview== | ||
According to the | According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms. The stages include at risk of AS, progressive hemodynamic obstruction, severe asymptomatic AS, and symptomatic AS. | ||
==Classification== | ==Classification== | ||
According to the | According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms of the patient: | ||
* '''A''': Patient at risk of AS | * '''A''': Patient at risk of AS | ||
* '''B''': Progressive hemodynamic obstruction | * '''B''': Progressive hemodynamic obstruction | ||
Line 22: | Line 22: | ||
Hemodynamic severity is assessed by transaortic maximum velocity or mean pressure gradient in the presence of a normal transaortic flow rate. However, some patients with AS have a low transaortic flow rate due to: | Hemodynamic severity is assessed by transaortic maximum velocity or mean pressure gradient in the presence of a normal transaortic flow rate. However, some patients with AS have a low transaortic flow rate due to: | ||
* LV systolic dysfunction with a reduced LV ejection fraction (designated as D2) | * LV systolic dysfunction with a reduced LV ejection fraction (designated as D2) | ||
* Small hypertrophied LV with a low stroke volume (designated as D3) <ref name=" | * Small hypertrophied LV with a low stroke volume (designated as D3) <ref name="pmid33332150">{{cite journal |vauthors=Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C |title=2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines |journal=Circulation |volume=143 |issue=5 |pages=e72–e227 |date=February 2021 |pmid=33332150 |doi=10.1161/CIR.0000000000000923 |url=}}</ref> | ||
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center | {| style="border: 0px; font-size: 90%; margin: 3px;" align=center | ||
Line 73: | Line 72: | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | * Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | ||
* AVA typically ≤ 1.0 cm < | * AVA typically ≤ 1.0 cm<sup>2</sup> (or AVAi ≤ 0.6 cm<sup>2</sup>/m<sup>2) | ||
* Very severe AS: Aortic Vmax ≥ 5 m/s or mean ΔP ≥60 mmHg | * Very severe AS: Aortic Vmax ≥ 5 m/s or mean ΔP ≥60 mmHg | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
Line 88: | Line 87: | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | * Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | ||
* AVA typically ≤ 1.0 cm<sup>2</sup (or AVAi ≤ 0.6 cm<sup>2</sup/m<sup>2 | * AVA typically ≤ 1.0 cm<sup>2</sup> (or AVAi ≤ 0.6 cm<sup>2</sup>/m<sup>2) | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* LVEF <50% | * LVEF <50% | ||
Line 107: | Line 106: | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | * Aortic Vmax ≥ 4 m/s or mean ΔP ≥40 mmHg | ||
* AVA typically ≤ 1.0 cm<sup>2</sup (or AVAi ≤ 0.6 cm<sup>2</sup/m<sup>2</sup) but may be larger with mixed AS/AR | * AVA typically ≤ 1.0 cm<sup>2</sup> (or AVAi ≤ 0.6 cm<sup>2</sup>/m<sup>2</sup>) but may be larger with mixed AS/AR | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* LV diastolic dysfunction | * LV diastolic dysfunction | ||
Line 122: | Line 121: | ||
* Severe leaflet calcification with severely reduced leaflet motion | * Severe leaflet calcification with severely reduced leaflet motion | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* AVA ≤1.0 cm<sup>2</sup with resting aortic Vmax <4 m/s or mean ΔP <40 mmHg | * AVA ≤1.0 cm<sup>2</sup> with resting aortic Vmax <4 m/s or mean ΔP <40 mmHg | ||
* Dobutamine stress echocardiography shows AVA ≤ 1.0 cm<sup>2</sup with Vmax ≥4 m/s at any flow rate | * Dobutamine stress echocardiography shows AVA ≤ 1.0 cm<sup>2</sup> with Vmax ≥4 m/s at any flow rate | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* LV diastolic dysfunction | * LV diastolic dysfunction | ||
Line 138: | Line 137: | ||
* Severe leaflet calcification with severely reduced leaftlet motion | * Severe leaflet calcification with severely reduced leaftlet motion | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | ||
* AVA ≤1.0 cm<sup>2</sup with aortic Vmax <4 m/s or mean ΔP <40 mmHg | * AVA ≤1.0 cm<sup>2</sup> with aortic Vmax <4 m/s or mean ΔP <40 mmHg | ||
* AVAi ≤0.6 cm<sup>2</sup/m<sup>2</sup and | * AVAi ≤0.6 cm<sup>2</sup>/m<sup>2</sup> and | ||
* Stroke volume index < | * Stroke volume index <35 ml/m<sup>2</sup> | ||
* Measured when patient is normotensive (systolic BP <140 mmHg) | * Measured when patient is normotensive (systolic BP <140 mmHg) | ||
| style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | | | style="background: #DCDCDC; padding: 5px; text-align: left;" valign="top" | |
Latest revision as of 02:52, 29 June 2022
Resident Survival Guide |
Aortic Stenosis Microchapters |
Diagnosis |
---|
Treatment |
Percutaneous Aortic Balloon Valvotomy (PABV) or Aortic Valvuloplasty |
Transcatheter Aortic Valve Replacement (TAVR) |
Case Studies |
Aortic stenosis classification On the Web |
American Roentgen Ray Society Images of Aortic stenosis classification |
Directions to Hospitals Treating Aortic stenosis classification |
Risk calculators and risk factors for Aortic stenosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mandana Chitsazan, M.D. [2]
Overview
According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms. The stages include at risk of AS, progressive hemodynamic obstruction, severe asymptomatic AS, and symptomatic AS.
Classification
According to the 2020 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease, there are 4 stages of aortic stenosis based on the valve anatomy, valve hemodynamics, the left ventricular and vascular consequences of aortic obstruction, and the symptoms of the patient:
- A: Patient at risk of AS
- B: Progressive hemodynamic obstruction
- C: Severe asymptomatic AS
- D: Symptomatic AS
Hemodynamic severity is assessed by transaortic maximum velocity or mean pressure gradient in the presence of a normal transaortic flow rate. However, some patients with AS have a low transaortic flow rate due to:
- LV systolic dysfunction with a reduced LV ejection fraction (designated as D2)
- Small hypertrophied LV with a low stroke volume (designated as D3) [1]
Stage | Definition | Valve Anatomy | Valve Hemodynamics | Hemodynamic Consequences | Symptoms |
---|---|---|---|---|---|
A | At risk of AS |
|
|
|
|
B | Progressive AS |
|
|
|
|
C: | Asymptomatic severe AS | ||||
C1 | Asymptomatic severe AS |
|
|
|
|
C2 | Asymptomatic severe AS with LV dysfunction |
|
|
|
|
D: | Symptomatic severe AS | ||||
D1 | Symptomatic severe high-grade AS |
|
|
|
|
D2 | Symptomatic severe low-flow/low-gradient AS with reduced LVEF |
|
|
|
|
D3 | Symptomatic severe low-gradient AS with normal LVEF or paradoxical low-flow severe AS |
|
|
|
|
References
- ↑ Otto CM, Nishimura RA, Bonow RO, Carabello BA, Erwin JP, Gentile F, Jneid H, Krieger EV, Mack M, McLeod C, O'Gara PT, Rigolin VH, Sundt TM, Thompson A, Toly C (February 2021). "2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines". Circulation. 143 (5): e72–e227. doi:10.1161/CIR.0000000000000923. PMID 33332150 Check
|pmid=
value (help).